Screening of Potential HIV-1 Inhibitors/Replication Blockers Using Secure Lentiviral in Vitro System.

M M Prokofjeva; P V Spirin; D V Yanvarev; A V Ivanov; M S Novikov; O A Stepanov; M B Gottikh; S N Kochetkov; Boris Fehse; C Stocking; V S Prassolov

Screening of Potential HIV-1 Inhibitors/Replication Blockers Using Secure Lentiviral in Vitro System.

Standard

Screening of Potential HIV-1 Inhibitors/Replication Blockers Using Secure Lentiviral in Vitro System. / Prokofjeva, M M; Spirin, P V; Yanvarev, D V; Ivanov, A V; Novikov, M S; Stepanov, O A; Gottikh, M B; Kochetkov, S N; Fehse, Boris; Stocking, C; Prassolov, V S.

In: ACTA NATURAE, Vol. 3, No. 4, 4, 2012, p. 55-65.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Prokofjeva, MM, Spirin, PV, Yanvarev, DV, Ivanov, AV, Novikov, MS, Stepanov, OA, Gottikh, MB, Kochetkov, SN, Fehse, B, Stocking, C & Prassolov, VS 2012, 'Screening of Potential HIV-1 Inhibitors/Replication Blockers Using Secure Lentiviral in Vitro System.', ACTA NATURAE, vol. 3, no. 4, 4, pp. 55-65. <http://www.ncbi.nlm.nih.gov/pubmed/22649704?dopt=Citation>

APA

Prokofjeva, M. M., Spirin, P. V., Yanvarev, D. V., Ivanov, A. V., Novikov, M. S., Stepanov, O. A., Gottikh, M. B., Kochetkov, S. N., Fehse, B., Stocking, C., & Prassolov, V. S. (2012). Screening of Potential HIV-1 Inhibitors/Replication Blockers Using Secure Lentiviral in Vitro System. ACTA NATURAE, 3(4), 55-65. [4]. http://www.ncbi.nlm.nih.gov/pubmed/22649704?dopt=Citation

Vancouver

Prokofjeva MM, Spirin PV, Yanvarev DV, Ivanov AV, Novikov MS, Stepanov OA et al. Screening of Potential HIV-1 Inhibitors/Replication Blockers Using Secure Lentiviral in Vitro System. ACTA NATURAE. 2012;3(4):55-65. 4.

Bibtex

@article{400569489b9c4730ab67dea4730378a8,

title = "Screening of Potential HIV-1 Inhibitors/Replication Blockers Using Secure Lentiviral in Vitro System.",

abstract = "The development and usage of safe cell systems for testing agents which possess anti-HIV activity is a very important factor in the design of new drugs. We have described in detail a system we designed that is based on lentiviral vectors (Prokofjeva et. al.,Antiviral Therapy,in print) for swift and completely safe screening of potential HIV-1 replication inhibitors. The system enables one to test the efficiency of the inhibitory activity of compounds whose action is directed towards either wild-type HIV-1 reverse transcriptase or integrase, or mutant enzymes corresponding to the drug-resistant virus form. Testing results of a number of already known drugs, which correlate well with published data as well as data on newly synthesized compounds, were obtained. Application of this system substantially broadens the possibilities of preclinical anti-HIV drugs testing.",

author = "Prokofjeva, {M M} and Spirin, {P V} and Yanvarev, {D V} and Ivanov, {A V} and Novikov, {M S} and Stepanov, {O A} and Gottikh, {M B} and Kochetkov, {S N} and Boris Fehse and C Stocking and Prassolov, {V S}",

year = "2012",

language = "English",

volume = "3",

pages = "55--65",

number = "4",

}

RIS

TY - JOUR

T1 - Screening of Potential HIV-1 Inhibitors/Replication Blockers Using Secure Lentiviral in Vitro System.

AU - Prokofjeva, M M

AU - Spirin, P V

AU - Yanvarev, D V

AU - Ivanov, A V

AU - Novikov, M S

AU - Stepanov, O A

AU - Gottikh, M B

AU - Kochetkov, S N

AU - Fehse, Boris

AU - Stocking, C

AU - Prassolov, V S

PY - 2012

Y1 - 2012

N2 - The development and usage of safe cell systems for testing agents which possess anti-HIV activity is a very important factor in the design of new drugs. We have described in detail a system we designed that is based on lentiviral vectors (Prokofjeva et. al.,Antiviral Therapy,in print) for swift and completely safe screening of potential HIV-1 replication inhibitors. The system enables one to test the efficiency of the inhibitory activity of compounds whose action is directed towards either wild-type HIV-1 reverse transcriptase or integrase, or mutant enzymes corresponding to the drug-resistant virus form. Testing results of a number of already known drugs, which correlate well with published data as well as data on newly synthesized compounds, were obtained. Application of this system substantially broadens the possibilities of preclinical anti-HIV drugs testing.

AB - The development and usage of safe cell systems for testing agents which possess anti-HIV activity is a very important factor in the design of new drugs. We have described in detail a system we designed that is based on lentiviral vectors (Prokofjeva et. al.,Antiviral Therapy,in print) for swift and completely safe screening of potential HIV-1 replication inhibitors. The system enables one to test the efficiency of the inhibitory activity of compounds whose action is directed towards either wild-type HIV-1 reverse transcriptase or integrase, or mutant enzymes corresponding to the drug-resistant virus form. Testing results of a number of already known drugs, which correlate well with published data as well as data on newly synthesized compounds, were obtained. Application of this system substantially broadens the possibilities of preclinical anti-HIV drugs testing.

M3 - SCORING: Journal article

VL - 3

SP - 55

EP - 65

IS - 4

M1 - 4

ER -